Physician profile
Aaron Steen
NPI 1093169633
$5,310.54
in general payments reported to CMS, 2019-2025
30 companies · $1,213 in 2025
The $1,213 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.99 · 2021: $61.43 · 2022: $487 · 2023: $1,761 · 2024: $1,763 · 2025: $1,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,737.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $637.11 | 2021-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $622.84 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $556.26 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $543.43 | 2022-2024 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $399.88 | 2022-2025 | Adbry, Anzupgo |
| Ucb, INC. | $381.53 | 2024-2025 | Bimzelx |
| Janssen Biotech, INC. | $349.56 | 2022-2025 | Tremfya |
| Genzyme Corporation | $283.15 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $231.80 | 2022-2025 | Absorica Ld, Winlevi, Blu-U |
| Lumenis Be INC | $190.70 | 2023 | M22 |
| Pfizer INC. | $160.49 | 2023-2024 | |
| Incyte Corporation | $149.13 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $132.75 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $125.00 | 2023 | Vtama |
| Galderma Laboratories, L.P. | $69.45 | 2023-2024 | Aklief |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $53.67 | 2023 | |
| Genentech USA, INC. | $53.62 | 2019-2024 | Xolair |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $44.47 | 2023 | Siliq, Targretin |
| Amgen INC. | $42.78 | 2023-2024 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.91 | 2024-2025 | Spevigo |
| Journey Medical Corporation | $38.42 | 2022 | |
| Botanix Sb INC | $30.77 | 2025 | Sofdra |
| Conmed Corporation | $30.39 | 2025 | Visiclear |
| Organogenesis INC. | $25.41 | 2023 | Puraply |
| Lnhc, INC | $20.61 | 2025 | Zelsuvmi |
| Mimedx Group, INC. | $20.27 | 2024 | |
| Verrica Pharmaceuticals INC. | $20.18 | 2024 | Ycanth |
| Paratek Pharmaceuticals, INC. | $20.09 | 2022 | |
| Vyne Pharmaceuticals INC. | $19.88 | 2021 | |
| Sebela Pharmaceuticals INC. | $14.99 | 2023 | Naftin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Steen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.